2′,3′,4′-Trihydroxychalcone changes estrogen receptor α regulation of genes and breast cancer cell proliferation by a reprogramming mechanism

BACKGROUND: Menopausal hormone therapy (MHT) is recommended for only five years to treat vasomotor symptoms and vulvovaginal atrophy because of safety concerns with long-term treatment. We investigated the ability of 2′,3′,4′-trihydroxychalcone (2′,3′,4′-THC) to modulate estrogen receptor (ER)-media...

Descripción completa

Detalles Bibliográficos
Autores principales: Herber, Candice B., Yuan, Chaoshen, Chang, Anthony, Wang, Jen-Chywan, Cohen, Isaac, Leitman, Dale C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9036729/
https://www.ncbi.nlm.nih.gov/pubmed/35468719
http://dx.doi.org/10.1186/s10020-022-00470-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9036729/
https://www.ncbi.nlm.nih.gov/pubmed/35468719
http://dx.doi.org/10.1186/s10020-022-00470-z

Ejemplares similares